Biotage Joins Forces with MultiSynTech and Enters the Peptide Synthesis Business
News Feb 24, 2009
Biotage announced that the company will enter the peptide synthesis business, through two new agreements with German company MultiSynTech GmbH. The agreements concern both the distribution rights for MultiSynTechs systems and the establishment of a joint development project.
The agreements with MultiSynTech will grant Biotage distribution rights for all current MultiSynTech peptide synthesis systems. Biotage and MultiSynTech have also agreed on a joint development project to design and market a new microwave-aided peptide synthesis system, which will increase yield and speed in peptide synthesis.
Demand for synthetic peptides is currently growing rapidly. The peptide synthesizer market is estimated at SEK 150m and is growing at double digit rate. In the research phase, biochemists need increasingly longer, more complex peptides to study protein interactions, produce peptide antibodies, and understand complex disease states. As the number and complexity of peptides increase, the biochemists need new tools that offer higher productivity and increased performance.
The Biotage - MultiSynTech collaboration will create those new tools that University and biopharmaceutical peptide research groups and contract peptide labs need to meet the new challenges in peptide synthesis. Biotage will be uniquely positioned to offer both parallel synthesis and microwave synthesis capability to address the full range of needs.
We look forward to working in close collaboration with Biotage. Biotage has a proven sales and support team that dramatically expands our coverage outside Central Europe, and really opens opportunities for our current products in USA, UK, Nordic and Asian regions, says Udo Treffer, CEO of MultiSynTech.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Eating Activates Calorie-Burning FatNews
The importance of the human brown adipose tissue (BAT) has become clearer during the past ten years. Coldness is one of the most effective activators of the BAT metabolic function but, in rodents, eating has also been shown to activate BAT. The debate on whether eating has the same effect on humans has lasted for decades. Now, the researchers at Turku PET Centre have proven that having a meal increases oxygen consumption in human BAT to the same extent as coldness.READ MORE